- On 5th October 2018
Professor Dave Singh is the Medical Director to the Medicines Evaluation Unit, and Professor of Clinical Pharmacology and Respiratory Medicine at the University of Manchester. He was a keynote speaker at this year’s European Respiratory Society International Congress in Paris on September 18th.
He presented data from a Phase II multicentre study of a first-in-class dual PDE3/4 inhibitor, which improved both airflow obstruction and symptoms in patients with COPD.
“The inhaled agent prompted sustained bronchodilation over 4 weeks and reduced the use of rescue salbutamol. Many patients on bronchodilators still suffer with a significant burden of symptoms, exacerbations and, for some, accelerated lung function decline. For patients with COPD, inhaled steroids are currently used to address inflammation and bronchodilators are used to target symptoms. But this molecule addresses both features. PDE3 inhibitors alleviate smooth muscle constriction, whereas PDE4 inhibitors have anti-inflammatory effects.” explained Professor Singh.
The data was well-received by the audience, who identified a need for new COPD treatment options.
Professor Singh also gave a talk regarding the role of eosinophils in the treatment of COPD during the congress: “Blood eosinophil counts can be used in COPD patients to predict the response to inhaled corticosteroids. There is a wealth of very consistent data showing the higher eosinophil counts predict a better drug response. This biomarker can be used in clinical practice as part of a precision medicine approach, targeting corticosteroids towards the patients most likely to benefit.”